PARATEK PHARMACEUTICALS INC (PRTK)

US6993743029 - Common Stock

2.23  +0.04 (+1.83%)

After market: 2.23 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PRTK. PRTK was compared to 203 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PRTK have multiple concerns. PRTK shows excellent growth, but is valued quite expensive already.



1

1. Profitability

1.1 Basic Checks

In the past year PRTK has reported negative net income.
In the past year PRTK has reported a negative cash flow from operations.
In the past 5 years PRTK always reported negative net income.
PRTK had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The profitability ratios for PRTK are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PRTK has a better Gross Margin (85.71%) than 89.57% of its industry peers.
PRTK's Gross Margin has improved in the last couple of years.
PRTK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

PRTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRTK has more shares outstanding than it did 1 year ago.
PRTK has more shares outstanding than it did 5 years ago.
PRTK has a worse debt/assets ratio than last year.

2.2 Solvency

PRTK has an Altman-Z score of -9.64. This is a bad value and indicates that PRTK is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.64, PRTK is doing worse than 75.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.64
ROIC/WACCN/A
WACC7.65%

2.3 Liquidity

PRTK has a Current Ratio of 0.52. This is a bad value and indicates that PRTK is not financially healthy enough and could expect problems in meeting its short term obligations.
PRTK has a Current ratio of 0.52. This is amonst the worse of the industry: PRTK underperforms 92.42% of its industry peers.
PRTK has a Quick Ratio of 0.52. This is a bad value and indicates that PRTK is not financially healthy enough and could expect problems in meeting its short term obligations.
PRTK's Quick ratio of 0.46 is on the low side compared to the rest of the industry. PRTK is outperformed by 92.42% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.46

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.67% over the past year.
The Revenue has grown by 59.83% in the past year. This is a very strong growth!
PRTK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 66.25% yearly.
EPS 1Y (TTM)35.67%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q24.24%
Revenue 1Y (TTM)59.83%
Revenue growth 3Y113.19%
Revenue growth 5Y66.25%
Revenue growth Q2Q34.94%

3.2 Future

The Earnings Per Share is expected to grow by 31.93% on average over the next years. This is a very strong growth
PRTK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.58% yearly.
EPS Next Y32.14%
EPS Next 2Y41.42%
EPS Next 3Y26.53%
EPS Next 5Y31.93%
Revenue Next Year9.93%
Revenue Next 2Y25.23%
Revenue Next 3Y14.33%
Revenue Next 5Y22.58%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRTK. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as PRTK's earnings are expected to grow with 26.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y26.53%

0

5. Dividend

5.1 Amount

PRTK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PARATEK PHARMACEUTICALS INC

NASDAQ:PRTK (9/20/2023, 7:00:00 PM)

After market: 2.23 0 (0%)

2.23

+0.04 (+1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap127.82M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 85.71%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.52
Quick Ratio 0.46
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)35.67%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y32.14%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)59.83%
Revenue growth 3Y113.19%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y